{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:44:22Z","timestamp":1781909062265,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s13300-020-00892-0","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T17:02:46Z","timestamp":1596042166000},"page":"2089-2104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog\u00ae in Japanese Patients with Type\u00a01 Diabetes: PRONTO-T1D Subpopulation Analysis"],"prefix":"10.1007","volume":"11","author":[{"given":"Junnosuke","family":"Miura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Imori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"892_CR1","unstructured":"World Health Organization (WHO). Global report on diabetes 2016. Geneva: WHO; 2016. https:\/\/www.who.int\/diabetes\/global-report\/en\/. Accessed 11 Mar 2020."},{"key":"892_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/BMI.S38440","volume":"11","author":"SI Sherwani","year":"2016","unstructured":"Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights. 2016;11:95\u2013104.","journal-title":"Biomarker Insights"},{"issue":"Suppl 2","key":"892_CR3","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.2337\/dc11-s216","volume":"34","author":"E Bonora","year":"2011","unstructured":"Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34(Suppl 2):S184\u2013S190190.","journal-title":"Diabetes Care"},{"key":"892_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","volume":"37","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2019. Abridged for primary care providers. Clin Diabetes. 2019;37:11\u201334.","journal-title":"Clin Diabetes"},{"key":"892_CR5","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Stark Casagrande","year":"2013","unstructured":"Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010. Diabetes Care. 2013;36:2271\u20139.","journal-title":"Diabetes Care"},{"key":"892_CR6","unstructured":"Japan Diabetes Clinical Data Management Study Group. 2018. https:\/\/jddm.jp\/data\/index-2017.html#data_03. Accessed 11 Mar 2020"},{"key":"892_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2337\/diacare.26.3.881","volume":"26","author":"L Monnier","year":"2003","unstructured":"Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881\u20135.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"892_CR8","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.2337\/dc11-s206","volume":"34","author":"E Standl","year":"2011","unstructured":"Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011;34(Suppl 2):S120\u2013S127127.","journal-title":"Diabetes Care"},{"key":"892_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jdiacomp.2015.09.019","volume":"30","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving? J Diabetes Compl. 2016;30:374\u201385.","journal-title":"J Diabetes Compl"},{"key":"892_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/archinte.161.3.397","volume":"161","author":"DECODE Study Group, the European Diabetes Epidemiology Group","year":"2001","unstructured":"DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch Intern Med. 2001;161:397\u2013405.","journal-title":"Arch Intern Med"},{"key":"892_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2337\/diacare.25.10.1845","volume":"25","author":"JB Meigs","year":"2002","unstructured":"Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845\u201350.","journal-title":"Diabetes Care"},{"key":"892_CR12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s001250050617","volume":"39","author":"M Hanefeld","year":"1996","unstructured":"Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577\u201383.","journal-title":"Diabetologia"},{"key":"892_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13300-016-0175-x","volume":"7","author":"M Brod","year":"2016","unstructured":"Brod M, Nikolajsen A, Weatherall J, Pfeiffer KM. Understanding post-prandial hyperglycemia in patients with type\u00a01 and type 2 diabetes: a web-based survey in Germany, the UK, and USA. Diabetes Ther. 2016;7:335\u201348.","journal-title":"Diabetes Ther"},{"key":"892_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/13696998.2017.1377208","volume":"21","author":"KM Pfeiffer","year":"2018","unstructured":"Pfeiffer KM, Sandberg A, Nikolajsen A, Brod M. Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin. J Med Econ. 2018;21:66\u201373.","journal-title":"J Med Econ"},{"key":"892_CR15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/193229681100500322","volume":"5","author":"L Heinemann","year":"2011","unstructured":"Heinemann L, Hompesch M, Flacke F, et al. Reduction of postprandial glycemic excursions in patients with type\u00a01 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol. 2011;5:681\u20136.","journal-title":"J Diabetes Sci Technol"},{"key":"892_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1177\/193229681200600406","volume":"6","author":"AH Boss","year":"2012","unstructured":"Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6:773\u20139.","journal-title":"J Diabetes Sci Technol"},{"key":"892_CR17","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1111\/dom.13442","volume":"20","author":"G Andersen","year":"2018","unstructured":"Andersen G, Meiffren G, Lamers D, et al. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type\u00a01 diabetes. Diabetes Obes Metab. 2018;20:2627\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"892_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/193229681200600408","volume":"6","author":"A Krasner","year":"2012","unstructured":"Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol. 2012;6:786\u201396.","journal-title":"J Diabetes Sci Technol"},{"key":"892_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1177\/193229681200600402","volume":"6","author":"L Heinemann","year":"2012","unstructured":"Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6:728\u201342.","journal-title":"J Diabetes Sci Technol"},{"key":"892_CR20","unstructured":"Humalog [prescribing information]. Eli Lilly and Company; 2015. https:\/\/pi.lilly.com\/us\/humalog-pen-pi.pdf. Accessed 25 Mar 2020"},{"key":"892_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14100","author":"L Klaff","year":"2020","unstructured":"Klaff L, Cao D, Dellva MA, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type\u00a01 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14100.","journal-title":"Diabetes Obes Metab"},{"key":"892_CR22","doi-asserted-by":"publisher","first-page":"108076","DOI":"10.1016\/j.diabres.2020.108076","volume":"162","author":"H Ishii","year":"2020","unstructured":"Ishii H, Suichi S, Williams P, Demiya S, Aranishi T, Treuer T. Cross-sectional survey in patients with type\u00a01 and type 2 diabetes to understand mealtime insulin unmet needs in Japan: the MINUTES-J study. Diabetes Res Clin Pract. 2020;162:108076.","journal-title":"Diabetes Res Clin Pract"},{"key":"892_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14656566.2016.1260547","volume":"18","author":"SI Harashima","year":"2017","unstructured":"Harashima SI, Nishimura A, Inagaki N. Attitudes of patients and physicians to insulin therapy in Japan: an analysis of the Global Attitude of Patients and Physicians in Insulin Therapy study. Expert Opin Pharmacother. 2017;18:5\u201311.","journal-title":"Expert Opin Pharmacother"},{"key":"892_CR24","unstructured":"World Health Organization (WHO). Classification of diabetes mellitus. Geneva: WHO; 2019. https:\/\/www.who.int\/publications-detail\/classification-of-diabetes-mellitus. Accessed 11 Mar 2020"},{"key":"892_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","volume":"7","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7:221\u201330.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"892_CR26","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1040-P","author":"J Leohr","year":"2020","unstructured":"Leohr J, Dellva MA, Carter K, et al. 1040-P Ultra-rapid lispro (URLi) accelerates insulin lispro absorption and insulin action vs. humalog (lispro) consistently across study populations: a meta-analysis of pharmacokinetic and glucodynamic data. Diabetes. 2020. https:\/\/doi.org\/10.2337\/db20-1040-P","journal-title":"Diabetes"},{"key":"892_CR27","doi-asserted-by":"publisher","unstructured":"Linnebjerg H, Zhang Q, LaBell E, et al. 1107-P: ultra rapid lispro (URLi) accelerates insulin lispro absorption and insulin action vs. Humalog\u00ae (lispro) in patients with T1D. Diabetes. 2019;68:(Suppl 1). https:\/\/doi.org\/10.2337\/db19-1107-P.","DOI":"10.2337\/db19-1107-P"},{"key":"892_CR28","doi-asserted-by":"crossref","unstructured":"Plum-Moerschel L, Leohr J, Liu, R, et al. 1010-P\u2014ultra-rapid lispro (URLi) reduces postprandial glucose excursions vs. Humalog\u00ae in patients with T1D at multiple meal-to-dose timing intervals. Amercican Diabetes Association 78th Scientific Session. 2018. https:\/\/plan.core-apps.com\/tristar_ada18\/abstract\/807d2f9885450670bb994661e3fdd160.","DOI":"10.2337\/db18-1010-P"},{"key":"892_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13195","author":"M Shiramoto","year":"2019","unstructured":"Shiramoto M, Nasu R, Oura T, Imori M, Ohwaki K. Ultra-rapid lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog\u00ae in Japanese patients with type\u00a01 diabetes. J Diabetes Investig. 2019. https:\/\/doi.org\/10.1111\/jdi.13195.","journal-title":"J Diabetes Investig"},{"key":"892_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2337\/diab.34.6.580","volume":"34","author":"E Ferrannini","year":"1985","unstructured":"Ferrannini E, Bjorkman O, Reichard GA Jr, et al. The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes. 1985;34:580\u20138.","journal-title":"Diabetes"},{"key":"892_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.2337\/diacare.26.3.688","volume":"26","author":"DECODE Study Group, European Diabetes Epidemiology Group","year":"2003","unstructured":"DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688\u201396.","journal-title":"Diabetes Care"},{"key":"892_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233\u201340.","journal-title":"Diabetes Care"},{"key":"892_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13690-015-0088-6","volume":"73","author":"EB Ketema","year":"2015","unstructured":"Ketema EB, Kibret KT. Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systematic review and meta-analysis. Arch Public Health. 2015;73:43.","journal-title":"Arch Public Health"},{"key":"892_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.diabres.2006.11.011","volume":"77","author":"HJ Woerle","year":"2007","unstructured":"Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280\u20135.","journal-title":"Diabetes Res Clin Pract"},{"key":"892_CR35","unstructured":"European Medicines Agency. Liumjev. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/liumjev#authorisation-details-section. Accessed 2 Jun 2020"},{"key":"892_CR36","unstructured":"Pharmaceutical and Medical Devices Agency. Summary of investigation results. Preparations containing insulin. https:\/\/www.pmda.go.jp\/files\/000235075.pdf#page=4. Accessed 2 Jun 2020"},{"key":"892_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40262-019-00834-5","volume":"59","author":"H Haahr","year":"2020","unstructured":"Haahr H, Heise T. Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. Clin Pharmacokinet. 2020;59:155\u201372.","journal-title":"Clin Pharmacokinet"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00892-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T23:25:20Z","timestamp":1627514720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00892-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00892-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}